Loading...
New

Immuno-oncology Assay Market by Product (Consumables and Software), by Technology (Immunoassays, Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), and Flow Cytometry), Application (Research & Development and Clinical Diagnostics), and Indication (Colorectal Cancer, Lung Cancer, Melanoma, Bladder Cancer, and Others): Global Opportunity Analysis and Industry Forecast, 2019–2026

A06079
Pages: 289
Mar 2020 | 1300 Views
 
Author(s) : Kavita Joshi , Onkar Sumant
Tables: 130
Charts: 50
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Immuno-oncology Assay Market

Request Now !

The global immuno-oncology assay market accounted for $2,769 million in 2018, and is expected to reach $6,179 million by 2026, growing at a CAGR of 10.6% from 2019 to 2026.

The immuno-oncology assay is a type of immunoassay primarily used for cancer diagnosis. It is a procedure in which various analytes such as proteins, biomolecules, growth factors, cytokines, and chemokines are profiled by detecting and quantifying them simultaneously. This procedure majorly uses the body's natural defense system to target and destroy cancer cells. This assay is used as a tool for in vitro analysis to study the dynamic interactions between cancer cells & immune cells, intricate tumor microenvironment, perceiving immunoreactivity in a multitude of cell-based assays to predict mode of action, and pharmacodynamics. Moreover, immuno-oncology assay holds enormous potential in the R&D of drugs for the treatment of diseases, such as cancer and cardiovascular diseases. For instance, xMAP multiplex assay provides a platform for cancer biomarker assays, which are compatible with plasma, serum, cultured cells, and other biological samples. The American Association of Cancer Research (AACR) developed the multiplex immunoassay that helped in the examination of acquired resistance to receptor tyrosine kinase (RTK) inhibitors. RTK is used as a target for drug development for the treatment of cancer. 

Immuno Oncology Assay Market

Get more information on this report : Request Sample Pages

 

The immuno-oncology assay market is witnessing significant growth, owing to increase in R&D activities in pharmaceuticals for the treatment of cancer. These assays are used in clinical trials, as they decrease the cost of research & manual labor and increase the efficiency of experiments and therapies. Moreover, they allow to understand a compound’s response precisely intended to mimic the tumor microenvironment. Optimized cell-based assays deliver crucial information to confirm the efficiency of a drug or a compound in simple and progressively complex co-culture assays. In addition, they offer easier & faster analysis of cancer, and are automated as compared to conventional methods, thus fueling the immune-oncology assay market growth. However, high capital investment and dearth of skilled labors are the major factors that hinder the market growth. Conversely, technological development of automated immuno-oncology assay is projected to create lucrative opportunities for the market growth during the forecast period. In addition, surge in government initiatives towards biotech research is expected to create various opportunities in developing economies. For instance, developing countries such as India, Australia, and Mexico, the governments have invested in the development of healthcare, facilitating an increase in the number of clinical laboratories, hospitals, and research centers. According to the AACR, a 7% increase was witnessed in federal funding for the National Cancer Institute (NCI) and the National Institute of Health (NIH) in 2015. In addition, increase in prevalence of diseases, such as cancer, has enforced researchers to develop biomarkers and drugs for the detection and treatment of cancer. Hence, a multiplex assay panel for immuno-oncology analysis helps to meet the needs of pharmaceutical researchers, thus driving the market growth during the forecast period.

The global immuno-oncology assay market in this report is studied on the basis of product, technology, indication, application, and region. By product, the market is divided into consumables and software. Depending on technology, it is classified into immunoassay, polymerase chain reaction (PCR), next-generation sequencing (NGS), flow cytometry, and others. According to indication, it is segregated into colorectal cancer, lung cancer, melanoma, bladder cancer, and others. As per application, it is fragmented into clinical diagnostics and research. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Immuno-oncology Assay Market
By Product

Your browser does not support the canvas element.

Software segment is projected as one of the most lucrative segments.

Get more information on this report : Request Sample Pages

Product segment review

By product, the consumables segment held the largest share of 60% in 2018, and is anticipated to remain the same during the forecast period, due to the usage of several kinds of reagents, kits, instruments for performing the assays. However, software segment is anticipated to grow at the fastest rate during the forecast period.

Immuno-oncology Assay Market
By Technology

Your browser does not support the canvas element.

Immunoassay segment is projected as one of the most lucrative segments.

Get more information on this report : Request Sample Pages

Technology segment review

Depending on technology, the PCR segment accounted for the majority of market share in 2018, and is anticipated to continue its dominance during the forecast period. This is attributed to the wide usage of PCR while performing oncology diagnosis and research. In addition, technological advancements in PCR technology such as advent of real-time PCR contributes toward the growth of the segment.

Region wise, the immuno-oncology assay market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America dominated the market in 2018, accounting for the highest share, and is anticipated to maintain this trend throughout the forecast period. This is attributed to increase in funding by government agencies and rise in focus to develop novel drug and biomarkers in this region. However, as per immuno-oncology assay market forecast, Asia-Pacific is projected to register the highest growth rate from 2019 to 2026. This is attributed to rise in investment by the government as well as private companies for research activities. In addition, increase in penetrance of key players, including Thermo Fisher and Illumina, Inc., in this region fuels the growth of the immuno-oncology assay market.

Immuno-oncology Assay Market
By Region

2026
North America 
Europe
Asia-pacific
Lamea

Asia-Pacific region would exhibit the highest CAGR of 12.9% during 2019-2026.

Get more information on this report : Request Sample Pages

The major players operating in the global immuno-oncology assays market are Luminex Corporation, Thermo Fisher Scientific Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Becton, Dickinson and Company, Abcam PLC, Seegene Inc., Meso Scale Diagnostics LLC, and Randox Laboratories Ltd. These players have adopted product launch, collaboration, and merger & acquisition as their key developmental strategies. The other players (not included in the report) include Merck, Agilent Technologies, Quanterix, and Olink.

Key Benefits for Stakeholders:

  • The study provides an in-depth analysis of the global immuno-oncology assay market share with the current trends and future estimations to elucidate the imminent investment pockets.
  • A comprehensive analysis of the factors that drive and restrict the market is provided.
  • A comprehensive quantitative immuno-oncology assay market analysis is provided from 2018 to 2026 to assist stakeholders to capitalize on the prevailing opportunities.
  • An extensive analysis of the key segments of the industry helps to understand the global immuno-oncology assay market trends.
  • Key players and their strategies are provided to understand the competitive outlook of the industry.

Key Market Segments:

By Product

  • Consumables
  • Software

By Technology

  • Immunoassay
  • PCR
  • NGS
  • Flow Cytometry
  • Others

By Indication

  • Colorectal Cancer
  • Lung Cancer
  • Melanoma
  • Bladder Cancer
  • Others

By Application 

  • Clinical Diagnostics
  • Research

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • France
    • Germany
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • LAMEA 
    • Saudi Arabia
    • South Africa
    • Brazil
    • Rest of LAMEA
 

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. KEY FINDINGS OF THE STUDY
2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets

3.3. Top winning strategies
3.4. Porter’s five forces analysis

3.4.1. Moderate bargaining power of buyers
3.4.2. Low bargaining power of suppliers
3.4.3. Moderate threat of substitutes
3.4.4. Low threat of new entrants
3.4.5. Moderate competitive rivalry

3.5. Market share analysis, 2018
3.6. Market dynamics

3.6.1. Drivers

3.6.1.1. Increase in biotechnology R&D activities & governmental funding 
3.6.1.2. Surge in adoption of multiplex immuno-oncology assay to reduce operation costs
3.6.1.3. Rise in adoption of personalized medicines

3.6.2. Restraint

3.6.2.1. Dearth of skilled labor/healthcare professionals

3.6.3. Opportunity

3.6.3.1. Various growth opportunities in emerging economies

CHAPTER 4: IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT

4.1. Overview

4.1.1. Market size and forecast

4.2. Consumables

4.2.1. Key market trends and opportunities
4.2.2. Market size and forecast
4.2.3. Market share analysis, by country

4.3. Software

4.3.1. Key market trends and opportunities
4.3.2. Market size and forecast
4.3.3. Market share analysis, by country

CHAPTER 5: IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY

5.1. Overview

5.1.1. Market size and forecast

5.2. Immunoassays

5.2.2. Market size and forecast
5.2.3. Market share analysis, by country

5.3. Polymerase chain reaction (PCR)

5.3.1. Market size and forecast
5.3.2. Market share analysis, by country

5.4. Next-generation sequencing (NGS)

5.4.1. Market size and forecast
5.4.2. Market share analysis, by country

5.5. Flow cytometry

5.5.1. Market size and forecast
5.5.2. Market share analysis, by country

CHAPTER 6: IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION

6.1. Overview

6.1.1. Market size and forecast

6.2. Colorectal cancer

6.2.1. Market size and forecast
6.2.2. Market share analysis, by country

6.3. Lung Cancer

6.3.1. Market size and forecast
6.3.2. Market share analysis, by country

6.4. Melanoma cancer

6.4.1. Market size and forecast
6.4.2. Market share analysis, by country

6.5. Bladder Cancer

6.5.1. Market size and forecast
6.5.2. Market share analysis, by country

6.6. Others

6.6.1. Market size and forecast
6.6.2. Market share analysis, by country

CHAPTER 7: IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION

7.1. Overview

7.1.1. Market size and forecast

7.2. Research & development

7.2.1. Market size and forecast
7.2.2. Market share analysis, by country

7.3. Clinical diagnostics

7.3.1. Market size and forecast
7.3.2. Market share analysis, by country

CHAPTER 8: IMMUNO-ONCOLOGY ASSAY MARKET, BY REGION

8.1. Overview

8.1.1. Market size and forecast

8.2. North America

8.2.1. Key market trends and opportunities
8.2.2. Market size and forecast, by country
8.2.3. North America market size and forecast, by product
8.2.4. North America market size and forecast, by technology
8.2.5. North America market size and forecast, by indication
8.2.6. North America market size and forecast, by application

8.2.6.1. U.S. market size and forecast, by product
8.2.6.2. U.S. market size and forecast, by technology
8.2.6.3. U.S. market size and forecast, by indication
8.2.6.4. U.S. market size and forecast, by application
8.2.6.5. Canada market size and forecast, by product
8.2.6.6. Canada market size and forecast, by technology
8.2.6.7. Canada market size and forecast, by indication
8.2.6.8. Canada market size and forecast, by application
8.2.6.9. Mexico market size and forecast, by product
8.2.6.10. Mexico market size and forecast, by technology
8.2.6.11. Mexico market size and forecast, by indication
8.2.6.12. Mexico market size and forecast, by application

8.3. Europe

8.3.1. Key growth factors and opportunities
8.3.2. Market size and forecast, by country
8.3.3. Europe market size and forecast, by product
8.3.4. Europe market size and forecast, by technology
8.3.5. Europe market size and forecast, by indication
8.3.6. Europe market size and forecast, by application

8.3.6.1. Germany market size and forecast, by product
8.3.6.2. Germany market size and forecast, by technology
8.3.6.3. Germany market size and forecast, by indication
8.3.6.4. Germany market size and forecast, by application
8.3.6.5. France market size and forecast, by product
8.3.6.6. France market size and forecast, by technology
8.3.6.7. France market size and forecast, by indication
8.3.6.8. France market size and forecast, by application
8.3.6.9. UK market size and forecast, by product
8.3.6.10. UK market size and forecast, by technology
8.3.6.11. UK market size and forecast, by indication
8.3.6.12. UK market size and forecast, by application
8.3.6.13. Italy market size and forecast, by product
8.3.6.14. Italy market size and forecast, by technology
8.3.6.15. Italy market size and forecast, by indication
8.3.6.16. Italy market size and forecast, by application
8.3.6.17. Rest of Europe market size and forecast, by product
8.3.6.18. Rest of Europe market size and forecast, by technology
8.3.6.19. Rest of Europe market size and forecast, by indication
8.3.6.20. Rest of Europe market size and forecast, by application

8.4. Asia-Pacific

8.4.1. Key growth factors and opportunities.
8.4.2. Asia-Pacific market size and forecast, by country
8.4.3. Asia-Pacific market size and forecast, by product
8.4.4. Asia-Pacific market size and forecast, by technology
8.4.5. Asia-Pacific market size and forecast, by indication
8.4.6. Asia-Pacific market size and forecast, by application

8.4.6.1. Japan market size and forecast, by product
8.4.6.2. Japan market size and forecast, by technology
8.4.6.3. Japan Market size and forecast, by indication
8.4.6.4. Japan market size and forecast, by application
8.4.6.5. China market size and forecast, by product
8.4.6.6. China market size and forecast, by technology
8.4.6.7. China market size and forecast, by indication
8.4.6.8. China market size and forecast, by application
8.4.6.9. India market size and forecast, by product
8.4.6.10. India market size and forecast, by technology
8.4.6.11. India market size and forecast, by indication
8.4.6.12. India market size and forecast, by application
8.4.6.13. Rest of Asia-Pacific market size and forecast, by product
8.4.6.14. Rest of Asia-Pacific market size and forecast, by technology
8.4.6.15. Rest of Asia-Pacific market size and forecast, by indication
8.4.6.16. Rest of Asia-Pacific market size and forecast, by application

8.5. LAMEA

8.5.1. Key growth factors and opportunities
8.5.2. LAMEA market size and forecast, by country
8.5.3. LAMEA market size and forecast, by product
8.5.4. LAMEA market size and forecast, by technology
8.5.5. LAMEA market size and forecast, by indication
8.5.6. LAMEA market size and forecast, by application

8.5.6.1. Brazil market size and forecast, by product
8.5.6.2. Brazil market size and forecast, by technology
8.5.6.3. Market size and forecast, by indication
8.5.6.4. Brazil market size and forecast, by application
8.5.6.5. Saudi Arabia market size and forecast, by product
8.5.6.6. Saudi Arabia market size and forecast, by technology
8.5.6.7. Market size and forecast, by indication
8.5.6.8. Saudi Arabia market size and forecast, by application
8.5.6.9. South Africa market size and forecast, by product
8.5.6.10. South Africa market size and forecast, by technology
8.5.6.11. South Africa market size and forecast, by indication
8.5.6.12. South Africa market size and forecast, by application
8.5.6.13. Rest of LAMEA market size and forecast, by product
8.5.6.14. Rest of LAMEA market size and forecast, by technology
8.5.6.15. Rest of LAMEA market size and forecast, by indication
8.5.6.16. Rest of LAMEA market size and forecast, by application

CHAPTER 9: COMPANY PROFILES

9.1. AGILENT TECHNOLOGIES, INC.

9.1.1. Company overview

9.1.1.1. Company snapshot

9.1.2. Operating business segments
9.1.3. Product portfolio
9.1.4. Business performance
9.1.5. Key strategic moves and developments

9.2. BIO-RAD LABORATORIES, INC.

9.2.1. Company overview
9.2.2. Company snapshot
9.2.3. Operating business segments
9.2.4. Product Portfolio
9.2.5. Business performance

9.3. Charles River Laboratories, Inc.

9.3.1. Company overview
9.3.2. Company snapshot
9.3.3. Operating business segments
9.3.4. Product portfolio
9.3.5. Business performance
9.3.6. Key strategic moves and developments

9.4. F. HOFFMANN-LA ROCHE LTD.

9.4.1. Company overview
9.4.2. Company snapshot
9.4.3. Operating business segments
9.4.4. Product portfolio
9.4.5. Business performance
9.4.6. Key strategic moves and developments

9.5. ILLUMINA, INC.

9.5.1. Company overview
9.5.2. Company snapshot
9.5.3. Operating business segments
9.5.4. Product portfolio
9.5.5. Business performance
9.5.6. Key strategic moves and developments

9.6. NanoString Technologies, Inc.

9.6.1. Company overview
9.6.2. Company snapshot
9.6.3. Operating business segments
9.6.4. Product portfolio
9.6.5. Business performance

9.7. PERKINELMER, INC.

9.7.1. Company overview
9.7.2. Company snapshot
9.7.3. Operating business segments
9.7.4. Product portfolio
9.7.5. Business performance
9.7.6. Key strategic moves and developments

9.8. QIAGEN N.V.

9.8.1. Company overview
9.8.2. Company snapshot
9.8.3. Operating business segments
9.8.4. Product portfolio
9.8.5. Business performance
9.8.6. Key strategic moves and developments

9.9. Sartorius AG

9.9.1. Company overview
9.9.2. Company snapshot
9.9.3. Operating business segments
9.9.4. Product portfolio
9.9.5. Business performance
9.9.6. Key strategic moves and developments

9.10. THERMO FISHER SCIENTIFIC, INC.

9.10.1. Company overview
9.10.2. Company snapshot
9.10.3. Operating business segments
9.10.4. Product portfolio
9.10.5. Business performance
9.10.6. Key strategic moves and developments

LIST OF TABLES

TABLE 01. GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 02. IMMUNO-ONCOLOGY ASSAY MARKET FOR CONSUMBALES, BY REGION, 2018–2026 ($MILLION)
TABLE 03. IMMUNO-ONCOLOGY ASSAY SOFTWARE MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 04. IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 05. IMMUNO-ONCOLOGY ASSAY MARKET, FOR IMMUNOASSAY, BY REGION, 2018–2026 ($MILLION)
TABLE 06. IMMUNO-ONCOLOGY ASSAY MARKET FOR PCR, BY REGION, 2018–2026 ($MILLION)
TABLE 07. IMMUNO-ONCOLOGY ASSAY MARKET FOR NEXT GENERATION SEQUENCING (NGS), BY REGION, 2018–2026 ($MILLION)
TABLE 08. IMMUNO-ONCOLOGY ASSAY MARKET FOR FLOW CYTOMETRY, BY REGION, 2018–2026 ($MILLION)
TABLE 09. GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 10. IMMUNO-ONCOLOGY ASSAY MARKET FOR COLORECTAL CANCER, BY REGION, 2018–2026 ($MILLION)
TABLE 11. IMMUNO-ONCOLOGY MARKET FOR LUNG CANCER, BY REGION, 2018–2026 ($MILLION)
TABLE 12. IMMUNO-ONCOLOGY MARKET FOR MELANOMA, BY REGION, 2018–2026 ($MILLION)
TABLE 13. IMMUNO-ONCOLOGY MARKET FOR BLADDER CANCER, BY REGION, 2018–2026 ($MILLION)
TABLE 14. IMMUNO-ONCOLOGY MARKET FOR OTHERS, BY REGION, 2018–2026 ($MILLION)
TABLE 15. IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 16. IMMUNO-ONCOLOGY ASSAY MARKET FOR RESEARCH & DEVELOPMENT, BY REGION, 2018–2026 ($MILLION)
TABLE 17. IMMUNO-ONCOLOGY ASSAY MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2018–2026 ($MILLION)
TABLE 18. GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 19. NORTH AMERICA IMMUNO-ONCOLOGY ASSAY MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 20. NORTH AMERICA IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 21. NORTH AMERICA IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 22. NORTH AMERICA IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 23. NORTH AMERICA IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 24. U.S. IMMUNO-ONCOLOGY ASSAY MARKET BY PRODUCT, 2018–2026 ($MILLION)
TABLE 25. U.S. IMMUNO-ONCOLOGY ASSAY MARKET BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 26. US IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 27. U.S. IMMUNO-ONCOLOGY ASSAY MARKET BY APPLICATION, 2018–2026 ($MILLION)
TABLE 28. CANADA IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 29. CANADA IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 30. CANADA IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 31. CANADA IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 32. MEXICO IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 33. MEXICO IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 34. MEXICO IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 35. MEXICO IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 36. EUROPE IMMUNO-ONCOLOGY ASSAY MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 37. EUROPE IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION),
TABLE 38. EUROPE IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 39. EUROPE IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 40. EUROPE IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 41. GERMANY IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 42. GERMANY IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 43. GERMANY IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 44. GERMANY IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 45. FRANCE IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 46. FRANCE IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 47. FRANCE AMERICA IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 48. FRANCE IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 49. UK IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 50. UK IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 51. UK IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 52. UK IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 53. ITALY IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 54. ITALY IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 55. ITALY IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 56. ITALY IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 57. REST OF EUROPE IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 58. REST OF EUROPE IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 59. REST OF EUROPE IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 60. REST OF EUROPE IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 61. ASIA-PACIFIC IMMUNO-ONCOLOGY ASSAY MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 62. ASIA-PACIFIC IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION),
TABLE 63. ASIA-PACIFIC IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 64. ASIA-PACIFIC IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 65. ASIA-PACIFIC IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 66. JAPAN IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 67. JAPAN IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 68. JAPAN IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 69. JAPAN IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 70. CHINA IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 71. CHINA IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 72. CHINA IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 73. CHINA IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 74. INDIA IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 75. INDIA IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 76. INDIA IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 77. INDIA IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 78. REST OF ASIA-PACIFIC IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 79. REST OF ASIA-PACIFIC IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 80. REST OF ASIA PACIFIC IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 81. REST OF ASIA-PACIFIC IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 82. LAMEA IMMUNO-ONCOLOGY ASSAY MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 83. LAMEA IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION),
TABLE 84. LAMEA IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 85. LAMEA IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 86. LAMEA IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 87. BRAZIL IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 88. BRAZIL IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 89. BRAZIL IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 90. BRAZIL IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 91. SAUDI ARABIA IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 92. SAUDI ARABIA IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 93. SAUDI ARABIA IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 94. SAUDI ARABIA IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 95. SOUTH AFRICA IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 96. SOUTH AFRICA IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 97. SOUTH AFRICA IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 98. SOUTH AFRICA IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 99. REST OF LAMEA IMMUNO-ONCOLOGY ASSAY MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 100. REST OF LAMEA IMMUNO-ONCOLOGY ASSAY MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 101. NORTH AMERICA IMMUNO-ONCOLOGY ASSAY MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 102. REST OF LAMEA IMMUNO-ONCOLOGY ASSAY MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 103. AGILENT: OPERATING SEGMENTS
TABLE 104. AGILENT: PRODUCT PORTFOLIO
TABLE 105. BIO-RAD: COMPANY SNAPSHOT
TABLE 106. BIO-RAD: OPERATING SEGMENTS
TABLE 107. BIO-RAD: PRODUCT PORTFOLIO
TABLE 108. CHARLES RIVER: COMPANY SNAPSHOT
TABLE 109. CHARLES RIVER: OPERATING SEGMENTS
TABLE 110. CHARLES RIVER: PRODUCT PORTFOLIO
TABLE 111. ROCHE: COMPANY SNAPSHOT
TABLE 112. ROCHE: OPERATING SEGMENTS
TABLE 113. ROCHE: PRODUCT PORTFOLIO
TABLE 114. ILLUMINA: COMPANY SNAPSHOT
TABLE 115. ILLUMINA: OPERATING SEGMENTS
TABLE 116. ILLUMINA: PRODUCT PORTFOLIO
TABLE 117. NANOSTRING: COMPANY SNAPSHOT
TABLE 118. NANOSTRING: PRODUCT PORTFOLIO
TABLE 119. PERKINELMER: COMPANY SNAPSHOT
TABLE 120. PERKINELMER: OPERATING SEGMENTS
TABLE 121. PERKINELMER: PRODUCT PORTFOLIO
TABLE 122. QIAGEN: COMPANY SNAPSHOT
TABLE 123. QIAGEN: OPERATING SEGMENTS
TABLE 124. QIAGEN: PRODUCT PORTFOLIO
TABLE 125. SARTORIUS: COMPANY SNAPSHOT
TABLE 126. SARTORIUS: OPERATING SEGMENTS
TABLE 127. SARTORIUS: PRODUCT PORTFOLIO
TABLE 128. THERMO FISHER: COMPANY SNAPSHOT
TABLE 129. THERMO FISHER: OPERATING SEGMENTS
TABLE 130. THERMO FISHER: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01. GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP WINNING STRATEGIES, BY YEAR, 2016–2019*
FIGURE 04. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2016–2019* (%)
FIGURE 05. TOP WINNING STRATEGIES, BY COMPANY, 2016–2019*
FIGURE 06. MARKET SHARE ANALYSIS, 2018
FIGURE 07. GLOBAL IMMUNO-ONCOLOGY ASSAY MARKET: DRIVERS, RESTRAINT, AND OPPORTUNITY
FIGURE 08. COMPARATIVE SHARE ANALYSIS OF IMMUNE-ONCOLOGY ASSAY MARKET FOR CONSUMABLES, BY COUNTRY, 2018 & 2026 (%)
FIGURE 09. COMPARATIVE SHARE ANALYSIS OF IMMUNO-ONCOLOGY ASSAY MARKETFOR SOFTWARE, BY COUNTRY, 2018 & 2026 (%)
FIGURE 10. COMPARATIVE SHARE ANALYSIS OF IMMUNO-ONCOLOGY ASSAY MARKET FOR IMMUNOASSAY, BY COUNTRY, 2018 & 2026 (%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF IMMUNO-ONCOLOGY ASSAY MARKET FOR PCR, BY COUNTRY, 2018 & 2026 (%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF IMMUNO-ONCOLOGY ASSAY MARKET FOR NEXT GENERATION SEQUENCING (NGS), BY REGION, 2018–2026 ($MILLION), BY COUNTRY, 2018 & 2026 (%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF IMMUNO-ONCOLOGY ASSAY MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2018 & 2026 (%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF IMMUNO-ONCOLOGY ASSAY MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2018 & 2026 (%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF IMMUNO-ONCOLOGY MARKET FOR LUNG CANCER, BY COUNTRY, 2018 & 2026 (%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF IMMUNO-ONCOLOGY ASSAY MARKET FOR MELANOMA, BY COUNTRY, 2018 & 2026 (%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF IMMUNO-ONCOLOGY ASSAY MARKET FOR BLADDER CANCER, BY COUNTRY, 2018 & 2026 (%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF IMMUNO-ONCOLOGY ASSAY MARKETFOR OTHERS , BY COUNTRY, 2018 & 2026 (%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF IMMUNO-ONCOLOGY ASSAY MARKET, FOR RESEARCH & DEVELOPMENT, BY COUNTRY, 2018 & 2026 (%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF IMMUNO-ONCOLOGY ASSAY MARKET, FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2018 & 2026 (%)
FIGURE 21. AGILENT: COMPANY SNAPSHOT
FIGURE 22. AGILENT: NET SALES, 2016–2018 ($MILLION)
FIGURE 23. AGILENT: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 24. AGILENT: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 25. BIO-RAD: NET SALES, 2016–2018 ($MILLION)
FIGURE 26. BIO-RAD: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 27. BIO-RAD: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 28. CHARLES RIVER: NET SALES, 2016–2018 ($MILLION)
FIGURE 29. CHARLES RIVER: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 30. CHARLES RIVER: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 31. ROCHE: NET SALES, 2016–2018 ($MILLION)
FIGURE 32. ROCHE: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 33. ROCHE: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 34. ILLUMINA: NET SALES, 2016–2018 ($MILLION)
FIGURE 35. ILLUMINA: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 36. REVENUE SHARE BY REGION, 2018 (%)
FIGURE 37. NANOSTRING: NET SALES, 2016–2018 ($MILLION)
FIGURE 38. NANOSTRING: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 39. PERKINELMER: NET SALES, 2016–2018 ($MILLION)
FIGURE 40. PERKINELMER: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 41. PERKINELMER: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 42. QIAGEN: NET SALES, 2016–2018 ($MILLION)
FIGURE 43. QIAGEN: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 44. QIAGEN: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 45. SARTORIUS: NET SALES, 2016–2018 ($MILLION)
FIGURE 46. SARTORIUS: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 47. SARTORIUS: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 48. THERMA FISHER: NET SALES, 2016–2018 ($MILLION)
FIGURE 49. THERMO FISHER: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 50. THERMO FISHER: REVENUE SHARE BY REGION, 2018 (%)

 
 

The utilization of immuno-oncology assays for diagnostic purposes and clinical research is increasing. This is attributed to the fact that clinical study for cancer is currently experiencing an exhilarating shift, as the range of accessible drugs has extended beyond chemotherapy to new molecularly targeted therapies. In addition, these assays increase the efficiency of experiments in clinical laboratories for biomarker validation and diagnosis & treatment of diseases. Furthermore, recent innovations and constant developments in this field have fueled the adoption of this these assays across various applications. For instance, Seegene in 2018, developed world’s first multiplex MDx assays with artificial intelligence (AI) system. The performance of these assays developed by using AI is superior better than as compared to manually developed assays.

Moreover, immuno-oncology assay are used prominently for clinical research, due to increase in R&D activities to introduce novel drug therapies. According to the CXOs, increase in economic strength of the developing nations such as China, India, Indonesia, and Thailand, and others and rise in healthcare expenditure and coupled with government funding for R&D are expected to drive the market growth during the forecast period. North America and Europe are expected to dominate the market of immuno-oncology assay during the forecast period, while emerging countries in Asia-Pacific and Latin America are expected to offer significant growth opportunities.

 

PURCHASE OPTIONS

Start reading instantly ,This title and over 12000 thousand more,available with Avenue Library,  T&C*

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,   
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com

FREQUENTLY ASKED QUESTIONS?
 

A. The market vaule of global Immuno-Oncology Assays market was $2,769.5 million in 2018.

A. The forecast period is from 2019 to 2026.

A. The market value of global Immuno-Oncology Assays market in 2019 is $6,179.2 million.

A. The adoption of Immuno-Oncology Assays is expected to increase due to surge in prevalance of cancer across the globe.

A. No, the report does not provides value chain analysis.

A. Introduction of multiplex assays.

A. Emerging countries of Asia-Pacific region are growing at a growth rate of 12.9%. China, India, are expected grow at a CAGR of 15.5% and 14.3% respectively.

A. The North America market held a major share in the Immuno-Oncology Assays market in 2018 and is expected to continue the trend in the forecasting period.

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Immuno-oncology Assay Market

  • Online Only
  • $3,456
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $5,769
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $8,995
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 699/mo
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Start reading instantly.
    This title and over 12,000+ are available on the Avenue Library.  T&C*.

    Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts